Abstract

Background & Methods: The aim of the study is to evaluate efficacy, safety and cognitive profile of amisulpride per se and compare it against that of olanzpine in newly diagnosed schizophrenic patients. The psychiatrist and further assessed on the ICD – 10 Criteria. Results: During the study period change observed in BPRS score in amisulpride group was 15.75[SD:3.67] and in olanzapine group was 14.72 [SD:2.93]. This improvement was similar in both groups and was not statistically significant [p=0.56]. Scores in each visit for Token test [scores presented as mean of the scores in the test [SD] values]. [p<0.05] Conclusion: Results of clinical study showed that amisulpride and olanzapine are having equal efficacy in terms of improvement of positive and negative symptoms of schizophrenia. Results were analysed by Mann Whitney U test for unpaired samples. Efficacy was assessed by Brief Psychiatry Rating Scale [BPRS].

Description